Search results
Showing 466 to 480 of 2579 results for methods
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Awaiting development Reference number: GID-TA11784 Expected publication date: 21 July 2027
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation (HTG496)
Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of livers for transplantation in people of all ages. This involves using a machine to give an oxygenated solution to the donor liver until it is transplanted.
View recommendations for HTG496Show all sections
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]
Awaiting development Reference number: GID-TA11467 Expected publication date: TBC
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
In development Reference number: GID-TA11425 Expected publication date: TBC
Awaiting development Reference number: GID-TA11494 Expected publication date: TBC
Awaiting development Reference number: GID-TA11326 Expected publication date: TBC